Inhaled protein/peptide-based therapies for respiratory disease.
Asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are all chronic pulmonary diseases, albeit with different etiologies, that are characterized by airflow limitation, chronic inflammation, and abnormal mucus production/rheology. Small synthetic molecule-based therapies are commonly prescribed for all three diseases. However, there has been increased interest in "biologicals" to treat these diseases. Biologicals typically constitute protein- or peptide-based therapies and are often more potent than small molecule-based drugs. In this review, we shall describe the pros and cons of several different biological-based therapies for respiratory disease, including dornase alfa, a recombinant DNAase that reduces mucus viscosity and short palate lung and nasal epithelial clone 1 (SPLUNC1)-derived peptides that treat Na(+) hyperabsorption and rebalance CF airway surface liquid homeostasis.
Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina, 7102 Marsico Hall, 125 Mason Farm Road, Chapel Hill, NC, 27599-7248, USA.
Robert C
RC
Fellner
Spyryx Biosciences, 801-9 Capitola Drive, Durham, NC, 27713, USA.
Shawn T
ST
Terryah
Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina, 7102 Marsico Hall, 125 Mason Farm Road, Chapel Hill, NC, 27599-7248, USA. robert_tarran@med.unc.edu.|Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA. robert_tarran@med.unc.edu.
Robert
R
Tarran
Aerosolization; Alpha-1-antitrypsin (AAT); BPIFA1; Biotherapies; CFTR; ENaC; Goblet cell metaplasia; Inflammation; Mucociliary clearance; Nebulization; Neutrophil elastase (NE); Omalizumab; PLUNC; Pulmozyme